/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

MacroGenics, Inc.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.42 -0.0141(-1.41%) MGNX at 04 Dec 2025 04:38 PM Biotechnology
Lowest Today 1.37
Highest Today 1.46
Today’s Open 1.405
Prev. Close 1.42
52 Week High 3.64
52 Week Low 0.99
Day’s Range: Low 1.37 High 1.46
52-Week Range: Low 0.99 High 3.64
1 day return -
1 Week return -8.41
1 month return -1.04
3 month return -26.87
6 month return -5.35
1 year return -59.39
3 year return -77.82
5 year return -94.1
10 year return -

Institutional Holdings

BB Biotech AG Ord 15.71

Bellevue Group AG 15.69

Armistice Capital, LLC 9.43

Vanguard Group Inc 6.67

Wasatch Advisors LP 5.14

Wasatch Ultra Growth 4.47

Millennium Management LLC 3.19

Vanguard Total Stock Mkt Idx Inv 3.06

BlackRock Inc 2.88

EcoR1 Capital, LLC 2.54

Renaissance Technologies Corp 2.10

Jacobs Levy Equity Management, Inc. 1.59

Two Sigma Advisers, LLC 1.36

Jane Street Group LLC 1.20

Goldman Sachs Group Inc 1.10

Geode Capital Management, LLC 1.08

Connor Clark & Lunn Inv Mgmt Ltd 1.08

Vanguard Institutional Extnd Mkt Idx Tr 1.01

Dimensional Fund Advisors, Inc. 0.81

JPMorgan Chase & Co 0.73

Morgan Stanley - Brokerage Accounts 0.71

Vanguard VIF Small Co Gr 0.69

Macquarie Group Ltd 0.66

Macquarie Healthcare I 0.66

Two Sigma Investments LLC 0.64

Marshall Wace Asset Management Ltd 0.64

Fidelity Extended Market Index 0.54

iShares Biotechnology ETF 0.53

Schwab US Small-Cap ETF™ 0.48

Vanguard Strategic Equity Inv 0.30

Vanguard Strategic Small-Cap Equity Inv 0.30

Vanguard Explorer Inv 0.28

Wasatch Long Short Alpha Composite 0.27

Wasatch Long/Short Alpha Institutional 0.27

iShares Micro-Cap ETF 0.21

Vanguard Health Care ETF 0.20

Multi-Manager Small Cap Eq Strat Inst 0.20

Extended Equity Market Fund K 0.20

Bridgeway Ultra-Small Company Market 0.19

Fidelity Total Market Index 0.18

Market Status

Strong Buy: 2

Buy: 1

Hold: 6

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 89.83 M

PB Ratio 1.4445

PE Ratio 0.0

Enterprise Value -12.60 M

Total Assets 261.66 M

Volume 2133862

Company Financials

Annual Revenue FY23:58749000 58.7M, FY22:151941000 151.9M, FY21:75643000 75.6M, FY20:97764000 97.8M, FY19:62024000 62.0M

Annual Profit FY23:40882000 40.9M, FY22:144557000 144.6M, FY21:72992000 73.0M, FY20:97764000 97.8M, FY19:62024000 62.0M

Annual Net worth FY23:-9058000 -9.1M, FY22:-120021000 -120.0M, FY21:-190857000 -190.9M, FY20:-117782000 -117.8M, FY19:-151811000 -151.8M

Quarterly Revenue Q3/2025:72839000 72.8M, Q2/2025:22241000 22.2M, Q1/2025:13192000 13.2M, Q3/2024:110708000 110.7M, Q2/2024:10797000 10.8M

Quarterly Profit Q3/2025:59461000 59.5M, Q2/2025:13335000 13.3M, Q1/2025:7792000 7.8M, Q3/2024:108838000 108.8M, Q2/2024:6163000 6.2M

Quarterly Net worth Q3/2025:16822000 16.8M, Q2/2025:-36251000 -36.3M, Q1/2025:-41036000 -41.0M, Q3/2024:56309000 56.3M, Q2/2024:-55664000 -55.7M

Fund house & investment objective

Company Information MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.

Organisation Biotechnology

Employees 341

Industry Biotechnology

CEO Mr. Eric Blasius Risser

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow